Premium
LONG‐TERM RESULTS OF THE MULTICENTER PHASE II TRIAL WITH BENDAMUSTINE AND RITUXIMAB AS FIRST LINE TREATMENT FOR PATIENTS WITH MALT LYMPHOMA (MALT‐2008‐01).
Author(s) -
Salar A.,
DomingoDomenech E.,
Panizo C.,
Nicolás C.,
Bargay J.,
Muntañola A.,
Canales M.,
Bello J.,
Sancho J.,
Tomás J.,
Rodriguez M.,
Peñalver F.J.,
Palomera L.,
Grande C.,
SánchezBlanco J.J.,
Arranz R.,
Conde E.,
Garcia M.,
García J.F.,
Caballero D.,
Montalbán C.
Publication year - 2017
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.2437_137
Subject(s) - bendamustine , rituximab , medicine , gastroenterology , malt lymphoma , neutropenia , adverse effect , phases of clinical research , population , surgery , lymphoma , clinical trial , chemotherapy , environmental health